Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Ltd ADR (NQ: ATHE )

2.150 +0.020 (+0.94%)
Streaming Delayed Price Updated: 3:28 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,634
Open 2.100
Bid (Size) 2.130 (1)
Ask (Size) 2.170 (2)
Prev. Close 2.130
Today's Range 2.035 - 2.200
52wk Range 1.550 - 5.410
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Performance

YTD
-13.31%
-13.31%
1 Month
+25.73%
+25.73%
3 Month
+16.22%
+16.22%
6 Month
-20.37%
-20.37%
1 Year
-24.16%
-24.16%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
Via Investor's Business Daily
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nasdaq Down Over 100 Points; Alaska Air To Acquire Hawaiian Airlines
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Neurodegenerative Disease-Focused Alterity Therapeutics Stock Trading Over 200% Higher Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.